NEWS FROM OUR LAB
Professor Nicholas Turner has been elected a Fellow of the Royal Society (FRS)
Fellows are elected based on excellence in science via a peer-review process and are thus some of the most eminent scientists from the UK.
FURTHER NEWS FROM OUR LAB
CoeBio3 phase IV continues with the start of six new PhD students
CoeBio3 is the The Centre of Excellence for Biocatalysis, Biotransformations and Biocatalytic Manufacture. http://www.coebio3.manchester.ac.uk/
The centre is based in Manchester but supports PhD students at the University of York, The University of Liverpool and the University of Bristol. The program is supported by industrial affiliates from Merck, GSK, Novartis, AstraZeneca and more….
Professor Nicholas Turner will lead a “Prosperity Partnership” for
Developing new biocatalytic technologies for chemical manufacturing in the pharmaceutical industry
This AstraZeneca, Prozomix and The University of Manchester Prosperity Partnership will bring together their expertise to design and develop novel chemical manufacturing technologies, based upon engineered biocatalysts, with the aim of producing new therapeutic complex molecules.
Achieving this goal will require the generation of a new toolbox of biocatalysts that are able to catalyse particularly demanding transformations. This project has the potential to bring new medicines to patients, in addition to developing more sustainable manufacturing processes that reduce the impact on the environment.